Vall d'Hebron Research Institute

What Vall d'Hebron Research Institute does

Vall d'Hebron Research Institute (VHIR), legally Fundaci\u00f3 Institut de Recerca Hospital Universitari Vall d'Hebron, is a non-profit biomedical research foundation founded in 1994 and headquartered in Barcelona, Spain, within the Vall d'Hebron Barcelona Hospital Campus. The institute employs 2,609 staff, including 1,331 dedicated research personnel across 60+ research groups organized into six research areas (Global Health, Chronic Diseases & Aging, Woman & Child Health & Rare Diseases, Brain & Mind, Cancer, and Personalized Medicine/Advanced Therapies). VHIR conducts translational and clinical biomedical research across oncology, neuroscience, infectious diseases, gene and cell therapy, nanomedicine, microbiome research, and rare diseases, producing 1,501 publications in 2024 with an average impact factor of 7.13.

VHIR's core technology infrastructure comprises specialized core facilities \u2014 Biobanc, Animal Laboratory (LAS), Experimental Surgery Unit (ESU), High Technology Unit (UAT), Statistics and Bioinformatics Unit (UEB), Clinical Research Support Unit (USIC), and Functional Validation and Preclinical Research (FVPR) \u2014 alongside an eCORE collaborative research structure. The institute maintains an active patent portfolio covering diagnostics (PIDCAP for primary immunodeficiencies, biomarkers for endometrial cancer), therapeutics (MNK1/2 Inhibitor EB1, liposome-based enzyme delivery, TK2 deficiency treatment, podocyte-specific expression vectors), and software (Play PROA antimicrobial stewardship gamification tool). AI capabilities are applied across computer vision (MS lesion detection, malaria diagnosis), natural language processing (cancer genome interpretation), and optimization (stroke care).

The institute operates as a publicly-funded non-profit with diversified revenue streams: \u20ac29.05M in competitive research grants in 2024 from ISCIII, the European Commission, Generalitat de Catalunya, La Caixa, and other agencies; clinical trial services revenue from 1,039 active studies with 244 new studies initiated in 2024 (and a 2022 campus record of 1,761 active clinical trials); and innovation revenue of \u20ac1.37M from patents, licensing, and spin-offs (2 licensed patents and 1 spin-off approved in 2024). VHIR monetizes its research through technology licensing, industry co-development partnerships (Neurophet, Personalis, Qnomx, Danone), academic collaborations with UAB and international institutions, master's and PhD programs, and spin-off creation (NEMA-Health, Luceria). Customers include pharmaceutical and biotech companies seeking trial execution and dataset access, academic and research institutions engaging in collaborative projects, and ultimately patients and the Spanish healthcare system through translational research outcomes.

Name

Vall d'Hebron Research Institute

Legal name

Fundació Institut de Recerca Hospital Universitari Vall d'Hebron

Website

https://vhir.org

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Vall d'Hebron Research Institute (VHIR) is a Barcelona-based non-profit biomedical research foundation operating 60+ research groups across six areas, serving pharmaceutical companies, academic institutions, and the healthcare system through clinical trials, translational research, and technology licensing.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Real-World Evidence (RWE) & HEOR for Development (HLAIALAI)

akta.pro secondary industries

Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD), Quality, Peer Review & Compliance Tools (MQSA/ACR/QA) (HLACALAL), Rare Ophthalmology Disorder Therapies (HLAIAIAK)

Keywords

• Biomedical research
• Clinical trials
• Translational medicine
• Medical innovation
• Healthcare research

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Research Grants and Funding: VHIR operates as a non-profit research institute funded through competitive research grants from public funding bodies including Instituto de Salud Carlos III, European Commission, La Caixa, and other national and international agencies
2. Clinical Trial Revenue: Revenue from conducting clinical studies and trials for pharmaceutical and biotech companies, with 244 new clinical studies and 1039 active clinical studies in 2024
3. Innovation Revenue: Revenue from innovation activities including patents, spin-offs, and technology licensing, with 2 licensed patents and 1 spin-off approved in 2024 generating 1.37 million euros

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Vall d'Hebron Research Institute (VHIR) is a public biomedical research foundation that conducts translational research across oncology, neuroscience, cardiology, infectious diseases, and other medical areas. The institute provides clinical trial services, maintains core research facilities, and offers specialized training programs including Master's degrees. VHIR also commercializes its research outputs through patent licensing and the creation of spin-off companies.

Product overview

Vall d'Hebron Research Institute (VHIR) is a biomedical research institution that does not offer commercial software products. However, it is involved in several technology collaborations and research initiatives: Neurophet AQUA MS (FDA 510(k)-cleared AI software for MS lesion detection from MRI), NeXT Personal MRD test (ultrasensitive minimal residual disease test for cancer monitoring), iMAGING AI diagnostic app for malaria, and various AI-assisted research platforms including Qnomx for pediatric oncology. VHIR provides research services, clinical trials management, and operates core facilities including Biobanc, Animal Laboratory, Experimental Surgery Unit, and High Technology Unit supporting biomedical research.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trials Services
• Core Research Facilities
• Master's Programs
• Patent Licensing and Spin-off Creation
• Collaborative Research Services

Quantifiable outcome

• 1501 publications with average impact factor 7.13
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and major.

• NeurophetcoreTechnology or Integration · 26 May 2026Joint research collaboration with Neurophet to develop and validate AI algorithms for detecting multiple sclerosis lesions based on MRI. Leverages VHIR's large-scale MRI datasets from over 1,000 clinically diagnosed MS patients to advance detection algorithms for Central Vein Sign and Paramagnetic Rim Lesions biomarkers.
• PersonaliscoreStrategic or Co-development Partner · 13 May 2026Clinical evidence generation supporting Personalis's NeXT Personal minimal residual disease test for immunotherapy monitoring. VHIR's clinical evidence contributed to Medicare coverage expansion for late-stage solid tumor patients.
• QnomxmajorStrategic or Co-development Partner · 9 March 202618-24 month clinical performance study evaluating Qnomx's AI-assisted summarization platform for cancer genome interpretation in pediatric oncology at VHIR's facilities.
• DanonemajorStrategic or Co-development Partner · 1 January 2024Collaboration to investigate modulatory effects of probiotics on gut immune system in patients with colorectal cancer and inflammatory bowel diseases, including collection of human intestinal explant tissues.
• Instituto de Salud Carlos III (ISCIII)coreOthersPrimary public funding body providing research grants and institutional accreditation for health research in Spain. VHIR maintains renewed accreditation as a health research institute.
• Autonomous University of Barcelona (UAB)coreStrategic or Co-development PartnerAcademic partner for joint research projects, educational programs including master's degrees, and technology development. Multiple co-development projects and patent applications with shared ownership.
• Vall d'Hebron HospitalcoreStrategic or Co-development PartnerIntegrated hospital campus providing clinical research infrastructure, patient access, and translational research environment. VHIR researchers work within the hospital setting to translate research into patient care.
• Vall d'Hebron Institute of Oncology (VHIO)coreStrategic or Co-development PartnerSpecialized oncology research institute within the Vall d'Hebron campus, collaborating on cancer research projects, clinical trials, and shared research facilities.

Scale indicators9 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• Centre for Genomic Regulation (CRG): Barcelona-based international biomedical research institute. Comparable as a publicly funded, internationally staffed research center in Spain with a similar funding mix (ISCIII, EU, CERCA) and overlapping focus areas in genomics, cell biology, and bioinformatics.
• IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer: Barcelona-based biomedical research institute linked to Hospital Clínic. Comparable as a Spanish hospital-anchored translational research institute competing for the same national and EU grant pools and pharma-sponsored clinical trials.
• Centro Nacional de Investigaciones Oncológicas (CNIO): Spain's national cancer research center in Madrid. Comparable as a large Spanish public biomedical research institute with hospital-adjacent operations, competitive grant capture, and active patent and spin-off pipeline — competing with VHIR for oncology talent, trials, and partnerships.
• IRB Barcelona: Research institute in Barcelona focused on computational biology, cancer, and translational biomedicine. Comparable peer in size, Spanish public-funding mix, and translational/biotech spin-out orientation, sharing talent pools and grant competition.
• Karolinska Institutet: Sweden's largest medical research university and a leading European biomedical research institute. Directly comparable as a public, hospital-anchored translational research institution running large clinical trial portfolios and translational programs across oncology, neuroscience, rare disease, and cell/gene therapy.
• Institut Pasteur: Non-profit biomedical research foundation in Paris with hospital-linked translational research, infectious disease focus, and a global scientific network. Comparable as a large European public research institute with mixed grant, philanthropy, and licensing revenue and active patent and spin-off activity.
• Francis Crick Institute: UK biomedical discovery research institute with >1,500 scientists and significant public/charitable funding. Comparable scale and translational posture to VHIR, with overlapping research themes (cancer, neuroscience, immunology) and similar non-profit, grant-funded model.
• Vall d'Hebron Institute of Oncology (VHIO): Oncology-focused research institute co-located on the Vall d'Hebron campus. Direct peer sharing infrastructure, hospital access, faculty overlap, and clinical trial pipelines with VHIR; jointly governed and the most operationally intertwined comparable.

Broad incumbents

• Massachusetts General Hospital Research Institute / Mass General Brigham: Large US hospital-anchored biomedical research enterprise. Comparable as a much larger translational research organization with deep pharma-sponsored clinical trial programs and broader geographic reach — a 'broad incumbent' benchmark rather than a direct competitor.
• Broad Institute of MIT and Harvard: US-based genomics and biomedical research institute with large-scale computational biology, AI-driven diagnostics, and pharma partnerships. Comparable on AI/clinical genomics partnership models (e.g., Neurophet, Personalis collaborations at VHIR), but operates at substantially larger scale and global scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/vhir_
• YouTubeyoutube.com/c/vallhebroncampus
• Facebookfacebook.com/vhir.org
• LinkedInlinkedin.com/company/vhir-vall-d-hebron-institut-de-recerca
• Instagraminstagram.com/vallhebroncampus
• TikToktiktok.com/@vallhebroncampus

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vall d'Hebron Research Institute